By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

The choice isn't that hard.

Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...

Eli Lilly and Novo Nordisk were sued by a compounding pharmacy alleging anticompetitive practices in the GLP-1 weight-loss ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

The pharmaceutical leader continues to grab headlines.

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an average annual return of 37.44%. Currently, Eli Lilly and Co has a market ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.